SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following reports that the company is preparing a formal bid for eBay, a move aimed at transforming the retailer into a massive e-commerce player. The community is actively debating the logistics of how GameStop, with its current cash reserves, would finance an acquisition of a company significantly larger than itself, while bulls anticipate a potential short squeeze and accelerated growth.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing a sharp rally driven by heavy short interest and speculative momentum as traders position themselves ahead of the company's upcoming earnings report. The community is actively discussing the potential for a short squeeze, citing high borrow fees and limited share availability while debating the long-term strategic value of the stock's recent partnership and acquisition activity.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending as market participants debate the impact of the end of the de minimis tariff exemption on its cross-border revenue and overall profit margins. While some traders are analyzing potential downside risks and short-term volatility, others remain focused on the company's long-term reliance on AI-driven marketplace improvements and the collectibles market to sustain growth.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MullenArmy is actively rallying behind its SOL-based token, with community members coordinating to drive momentum and recreate the market cap surges seen in previous cycles. Discussions are heavily focused on potential price runs, community-led buy pressure, and calls for long-term holding to reach previous market cap milestones.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending following the announcement of a pivotal Phase 3 registration path for CAD-1005 in Heparin-Induced Thrombocytopenia, which followed a successful end-of-Phase 2 meeting with the FDA. While some investors are optimistic about the company's clinical progress and pipeline potential, a significant portion of the community is expressing frustration over frequent spam, bot activity, and concerns regarding the company's long-term financial stability and funding requirements.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity Inc. is trending following positive Phase 3 VIKTORIA-1 trial data, with the community closely tracking the potential for gedatolisib to become a new standard of care in breast cancer. Traders are currently focused on recent institutional accumulation, anticipation of further trial readouts, and speculation regarding future FDA approvals or potential M&A activity.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as investors digest the commercial launch of NEREUS for motion sickness while debating the company's prospects for a potential buyout by major pharmaceutical players like Eli Lilly or Novo Nordisk. The community remains focused on the firm's strategic focus on GLP-1 adjunct treatments and active pipeline developments, even as participants express frustration over persistent price volatility and the company's aggressive regulatory strategy.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2025 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is trending as the market reacts to aggressive institutional accumulation and a successful box office performance that has validated the studio's theatrical-first strategy. Investors and community members are actively discussing the potential for a high-premium buyout as analysts continue to raise price targets, fueling speculation that the studio has become a primary takeover target for larger media players.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is currently trending due to its launch of a value-focused menu featuring items under $3 and $4 breakfast deals, a strategic shift aimed at reversing recent traffic declines and appeasing budget-conscious diners. Community discussion remains heavily polarized between long-term investors highlighting the stock's defensive durability and dividend growth, and critics fixated on viral social media clips questioning the CEO's engagement with the product and ongoing concerns regarding food quality.

Pershing Square, Inc. operates as an alternative asset management company. It operates through the following business segments: Operating Assets, MPC,and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multifamily properties along with other real estate investments. The MPC segments offers the development and sale of land in large-scale, long-term community development projects. The Strategic Developments segment provides residential condominium and commercial property projects currently under development. The company was founded by William A. Ackman on December 17, 2003 and is headquartered in New York, NY.

Pershing Square Inc.

Pershing Square Inc

Pershing Square is attracting significant attention as investors react to the company's recent public listing alongside its closed-end fund, $PSUS. Community discussion is focused on understanding the distinction between the two entities, navigating the volatility following the IPO, and debating Bill Ackman's long-term strategy for building a successor to Berkshire Hathaway.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top Small Cap Stocks To Add to Your Watchlist - May 1st

Inflection Point Acquisition Corp. II, Direxion Daily MU Bull 2X Shares, Cue Biopharma, Esperion Therapeutics, and Akanda are the five Small Cap stocks to watch today, according to MarketBeat's stock...

This Market Is Moving Fast

The market is sending a clear signal: capital is flowing aggressively into platforms that can scale innovation, whether that’s next-generation immunotherapy, AI-driven digital ecosystems, or entirely new infrastructure for energy and materials. This week’s developments, from fresh biotech funding to explosive user growth in social platforms and bold pivots into clean energy, highlight a broader theme: investors are rewarding companies that are either accelerating commercialization or positioning themselves at critical bottlenecks in emerging industries. $CUE, $RDDT, $SOBR, $KBLB, $WTO, $AKAN

<ul class="summary-bullets"><li>Early market action suggests a pause after a blockbuster April rally led by AI and mega-cap tech.</li><li>The White House argued that a recent ceasefire resets the 60-day War Powers clock, while Iran threatened ‘painful strikes’ if U.S. attacks resume.&nbsp;&nbsp;</li><li>Berkshire Hathaway's annual meeting kicks off in Omaha today.</li></ul>U.S. stock futures were subdued early Friday as investors took a breather following a historic April, the best month for markets since 2020. Traders are watching for developments in the Middle East amid a critical deadline for the Trump administration. The White House argued that a recent ceasefire resets the 60-day War Powers clock, while Iran threatened ‘painful strikes’ if U.S. attacks resume.&nbsp;&nbsp;As of 4:00 a.m. ET on Friday: Dow, S&amp;P 500 and Nasdaq futures were flat, while Russell 2000 futures declined 0.1%.Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, has moved to ‘extremely bullish’ from ‘bullish’ territory, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has stayed in the ‘bullish’ territory after markets closed out April at record highs.&nbsp;Trending Stocks To WatchApple (AAPL):&nbsp;Stock rose 3% in early premarket trade after beating Q2 estimates and forecasting strong revenue growth despite supply constraints.&nbsp;Reddit (RDDT) is also seeing an post-earnings rally, surging 16% in early premarket trading.Rivian Automotive (RIVN)&nbsp;slipped 4% in early premarket trading as investors reacted to a lack of fresh details on the upcoming R2 SUV. While Nio Inc (NIO) slipped 3% after the Chinese EV maker reported a decline in April deliveries,&nbsp; casting a shadow over its SUV launch push.Roblox (RBLX):&nbsp;Tanked 22% after slashing its full-year bookings guidance well below analyst projections.&nbsp;Meta Inc (META):&nbsp;Investors will be tracking the ongoing child safety litigation in New Mexico, though ARK Invest added 47k shares on Thursday.&nbsp;Veeva Systems (VEEV): It is set to join the S&amp;P 500 on May 7, replacing Coterra Energy following its acquisition by Devon Energy. Michael Burry called it ‘undervalued’.Cue Biopharma (CUE)&nbsp;continued its upmove, rising another 40% in early premarket trading after it announced a $30 million private investment in public equity financing, an exclusive Phase 2 anti-IgE antibody license, and a CEO appointment.&nbsp;Other tickers trending on Stocktwits&nbsp;at the time of writing included Akanda Corp (AKAN), Sandisk Corp (SNDK), Eli Lilly (LLY), and Atlassian Corp (TEAM).Berkshire Hathaway’s annual meeting kicks off in Omaha today.&nbsp;Other Catalysts To WatchOn the economic front, traders will be watching the release of April manufacturing data.&nbsp;On earnings radar, watch out for quarterly reports from Exxon Mobil (XOM), Chevron (CVX), Aon (AON), Colgate-Palmolive (CL), Estee Lauder (EL), Church &amp; Dwight (CHD), AutoNation (AN), Terex (TEX), Lear (LEA), Cinemark (CNK), and WisdomTree (WT) before the bell today. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Take A Breather Near Highs: Why AAPL, META, RDDT, RBLX, CUE Are Keeping Traders Engaged Today

Data from Stocktwits shows that retail traders are bullish on SPY and QQQ again.

Nasdaq, S&P 500 Futures Pause After Best April Since 2020: Why AAPL, META, RDDT, RBLX, CUE Are In Focus

Equity

Data from Stocktwits shows that retail traders are bullish on SPY and QQQ again.


Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving?

Cue Biopharma Inc. shares surged 67.57% after announcing a $30M financing, anti-IgE antibody license, and new CEO.read more...

<ul class="summary-bullets"><li>The $30 million net proceeds from the placement will allow the company to advance its clinical pipeline, Cue said.</li><li>Cue also announced it has obtained an exclusive license from Ascendant Health Sciences for Ascendant-221, an experimental drug designed to treat certain allergic diseases.</li><li>The company named Shao-Lee Lin as its new President, Chief Executive Officer, and member of the Board of Directors, effective immediately.</li></ul> Shares of Cue Biopharma (CUE) jumped nearly 100% after-hours on Thursday after the clinical-stage biotech company announced changes collectively aimed at strengthening its cash position, expanding its clinical pipeline, and bringing in new leadership.The company announced a $30 million private placement, licensed a new clinical-stage drug candidate, and appointed a new CEO.<h2 class="st-heading-2">$30 Million Private Placement Bolsters Balance Sheet</h2>Cue Biopharma entered into a securities purchase agreement with certain accredited investors for a private placement expected to raise gross proceeds of approximately $30 million before fees and expenses.The company stated it will use the net proceeds to advance its clinical pipeline, support working capital, and fund general corporate purposes. The transaction is expected to close on or about May 4, 2026, subject to customary closing conditions.<h2 class="st-heading-2">Exclusive License Adds To Pipeline</h2>Cue Biopharma further announced it has obtained an exclusive license from Ascendant Health Sciences for Ascendant-221, an experimental drug designed to treat certain allergic diseases. The license covers all territories except mainland China, Hong Kong, Macau, and Taiwan.Cue plans to advance the asset into further studies, with near-term clinical data expected from an ongoing mid-stage trial in chronic spontaneous urticaria during the second half of 2026.The company said that it will pay Ascendant $15 million upfront as a license fee, followed by up to an aggregate of $676.5 million in additional potential payments upon the achievement of certain milestones, in addition to tiered royalties on future sales of the drug.<h2 class="st-heading-2">Veteran Executive Shao-Lee Lin Named New CEO</h2>Cue Biopharma also named Shao-Lee Lin as its new President, Chief Executive Officer, and member of the Board of Directors, effective immediately.Lin previously founded and led the pharma company ACELYRIN, where she raised over $1 billion in capital and took the company public at a valuation exceeding $2 billion within three years. She has held senior roles at Horizon Therapeutics, AbbVie, Gilead Sciences, and Amgen.<h2 class="st-heading-2">How Did CUE Retail Traders React?</h2>On Stocktwits, retail sentiment around CUE stock jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user voiced optimism on the licensing deal.<stembedurl>https://www.stocktwits.com/AlertsAndNews/message/651957851</stembedurl>Another use voiced hopes for the stock rallying as high as $50, implying a potential rally of about 100% from the stock’s last close.<stembedurl>https://www.stocktwits.com/Aburose/message/651956517</stembedurl>A third user opined that the after-hours rally was a result of manipulation and a short squeeze.<stembedurl>https://www.stocktwits.com/Erect4tech/message/651956070</stembedurl><a href="https://stocktwits.com/symbol/CUE">CUE stock</a> has fallen 35% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/meta-ceo-links-stock-drop-to-higher-capex-plans-team-cuts-and-more-apps-report/cZBMpgSReIX">Meta CEO Links Stock Drop To Higher Capex, Plans Team Cuts And More Apps: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cue Biopharma logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? 

Cue Biopharma company announced a $30 million private placement, licensed a new clinical-stage drug candidate, and appointed a new CEO.

The company announced a $30 million private placement, licensed a new clinical-stage drug candidate, and appointed a new CEO.


Cue Biopharma (NASDAQ:CUE) Raised to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Cue Biopharma from a "buy" rating to a "strong-buy" rating in a research note on Saturday...

Cue Biopharma (NASDAQ:CUE) Shares Gap Down - Here's Why

Cue Biopharma (NASDAQ:CUE) Shares Gap Down - Here's Why...

What's Behind The Drop In Cue Biopharma Stock Today?

Cue Biopharma, Inc. (NASDAQ:CUE) shares are tumbling on Wednesday after the company announced a reverse stock split.read more...

<ul><li>Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement in April 2025.&nbsp;</li><li>The company added on Wednesday that it is still eligible to earn up to $337.5 million more in additional research, development and commercial milestone-based payments.&nbsp;</li><li>CEO Lucinda Warren said that the company is pleased with the milestone payment as it progresses its lead autoimmune asset, CUE-401, toward the clinic.</li></ul>Shares of Cue Biopharma, Inc. (CUE) is on track to record its best session to date, if gains hold, after the company announced earlier this week that it will receive $7.5 million as milestone payment from an agreement with Boehringer Ingelheim.CUE stock is up 77% at the time of writing.<h2 class="st-heading-2">Cue- Boehringer Ingelheim Deal</h2>Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement in April 2025 &nbsp;to develop and commercialize Cue Biopharma’s CUE-501 product candidate for autoimmune diseases.Under the deal, Cue received an upfront payment of $12 million and is eligible to earn up to about $345 million in research, development and commercial milestone-based payments, as well as royalty payments on net sales.The company now expects a $7.5 million payment in May 2026. Cue Biopharma also said on Wednesday that it is still eligible to earn up to $337.5 million more in additional research, development, and commercial milestone-based payments.CEO Lucinda Warren said that the company is pleased with the milestone payment as it progresses its lead autoimmune asset, CUE-401, toward the clinic. In February, the company said that its preclinical data demonstrated that CUE-401 was well tolerated with no adverse events.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CUE stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user expressed optimism about the rally after a quiet period. “This is starting to get interesting,” they wrote<stembedurl>https://www.stocktwits.com/topstockalerts/message/649975686</stembedurl>Another user highlighted the possibility of additional payments under the deal.<stembedurl>https://www.stocktwits.com/Aburose/message/649968775</stembedurl><a href="https://stocktwits.com/symbol/CUE">CUE stock</a> has fallen 28% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/repl-stock-dives-after-fda-refuses-approval-for-skin-cancer-drug/cZJ0Kb3RIto">REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CUE Stock On Track For Best Day In History — Why Is Retail Optimistic?

Cue now expects a $7.5 million payment from Boehringer Ingelheim in May 2026.

Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim

Cue Biopharma stock jumps after $7.5 million milestone from Boehringer Ingelheim, with additional milestone potential and pipeline progress.read more...

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Continue higher

Sideways action

Retreat lower

What’s your read on the market for next week?

Stocktwits

Stocktwits Polls

Traders are closely watching high short interest levels, debating whether a massive squeeze will force a rally to $50 and beyond.

Skeptics are highlighting the risks of share dilution and offering potential, cautioning that recent gains may trigger a significant rug pull.

Investors are actively scouting for the next low-float runner to replicate recent momentum observed in related sector stocks.

CUE
Cue Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CUE News

CUECue Biopharma Inc